GERN Geron Corporation
USHealthcareAs of 2026-08-24
Why GERN matters now
Geron Corporation (GERN) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.52 with +0.00% on the session and $975.1M in market capitalization; recent performance reads 1-month +3.28% and YTD -4.55%.
The latest financial table shown here is Q1 2026, with revenue of $51.8M, net income of $-3.6M, and EPS of $-0.01. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -15.6%.
The latest indexable market news headline is "Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $6.00; recent insider activity includes Bir Dawn Carter filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
3.68
P/S
4.12
EV/EBITDA
-26.78
DCF Value
$-7.33
FCF Yield
-15.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
86.6%
Operating Margin
-19.1%
Net Margin
-35.5%
ROE
-28.9%
ROA
-13.0%
ROIC
-7.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $51.8M | $-3.6M | $-0.01 |
| Q4 2025 | $48.0M | $-31.1M | $-0.05 |
| FY 2025 | $183.9M | $-85.8M | $-0.13 |
| Q3 2025 | $47.2M | $-18.4M | $-0.03 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$5.89
Target (Median)
$6.00
Target Range
$4.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.60
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.